1. Home
  2. DXCM vs ARE Comparison

DXCM vs ARE Comparison

Compare DXCM & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DXCM
  • ARE
  • Stock Information
  • Founded
  • DXCM 1999
  • ARE 1994
  • Country
  • DXCM United States
  • ARE United States
  • Employees
  • DXCM N/A
  • ARE N/A
  • Industry
  • DXCM Medical/Dental Instruments
  • ARE Real Estate Investment Trusts
  • Sector
  • DXCM Health Care
  • ARE Real Estate
  • Exchange
  • DXCM Nasdaq
  • ARE Nasdaq
  • Market Cap
  • DXCM 28.0B
  • ARE 19.3B
  • IPO Year
  • DXCM 2005
  • ARE 1997
  • Fundamental
  • Price
  • DXCM $77.19
  • ARE $102.67
  • Analyst Decision
  • DXCM Buy
  • ARE Buy
  • Analyst Count
  • DXCM 17
  • ARE 11
  • Target Price
  • DXCM $98.00
  • ARE $128.36
  • AVG Volume (30 Days)
  • DXCM 3.4M
  • ARE 1.2M
  • Earning Date
  • DXCM 02-06-2025
  • ARE 01-27-2025
  • Dividend Yield
  • DXCM N/A
  • ARE 5.07%
  • EPS Growth
  • DXCM 83.21
  • ARE 18.05
  • EPS
  • DXCM 1.67
  • ARE 1.64
  • Revenue
  • DXCM $3,954,000,000.00
  • ARE $3,085,452,000.00
  • Revenue This Year
  • DXCM $13.10
  • ARE N/A
  • Revenue Next Year
  • DXCM $14.79
  • ARE $2.15
  • P/E Ratio
  • DXCM $46.29
  • ARE $62.41
  • Revenue Growth
  • DXCM 16.19
  • ARE 10.21
  • 52 Week Low
  • DXCM $62.34
  • ARE $101.39
  • 52 Week High
  • DXCM $142.00
  • ARE $133.51
  • Technical
  • Relative Strength Index (RSI)
  • DXCM 51.88
  • ARE 35.70
  • Support Level
  • DXCM $77.33
  • ARE $103.38
  • Resistance Level
  • DXCM $81.12
  • ARE $107.19
  • Average True Range (ATR)
  • DXCM 2.43
  • ARE 2.23
  • MACD
  • DXCM -0.23
  • ARE -0.28
  • Stochastic Oscillator
  • DXCM 43.60
  • ARE 11.64

About DXCM DexCom Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

About ARE Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Share on Social Networks: